By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nautilus Biotech 

1, rue Pierre Fontaine

Evry    91000  France
Phone: 33-0-1-60-87-54-60 Fax: 33-0-1-60-87-54-61


SEARCH JOBS


Industry
Biotechnology






Company News
Han All Pharmaceutical Co., Ltd. (009420.KS) Acquires Global Rights To Nautilus Biotech's Protein Engineering Technology For Developing Novel Oral And Injectable Therapeutic Proteins 6/29/2009 1:49:11 PM
Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug 5/21/2007 12:07:50 PM
Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug 5/14/2007 11:29:55 AM
Nautilus Biotech Closes EUR8.4 Million ($11.3 Million) Investment Funding 4/30/2007 1:48:36 PM
Nautilus Biotech Begins Phase I Clinical Trial in the USA for Subcutaneous Belerofon(R), its Long-Lasting, Interferon-Alpha Drug 4/2/2007 11:04:51 AM
Nautilus Biotech and Han All Pharmaceutical Co., Ltd. (009420.KS) Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea 3/6/2007 1:15:53 PM
Nautilus Biotech Announces IND Filing for Belerofon®, Its Oral, Long-lasting, Interferon-alpha Drug 3/2/2007 6:17:25 PM
Wyeth (WYE) And Nautilus Biotech Announce Collaboration To Develop Hemophilia Therapies 2/5/2007 9:33:48 AM
Nautilus Biotech And Creabilis Therapeutics Achieve Technical Milestone In Collaboration To Improve HMGB1 Box A For The Treatment Of Rage- And HMGB1-Related Pathologies 11/14/2006 10:41:43 AM
Nautilus Biotech Announces IND Filing For Its Injectable Long-Lasting Interferon-alpha, BELEROFON(R) 10/10/2006 10:57:27 AM
123
//-->